In an amicus brief authored by Paul Slater, the AAI urges the full Second Circuit to rethink two cases (Cipro and Tamoxifen) of great importance to keeping brand name manufacturers from paying competitive generic companies to keep their cheaper drugs off the market.
Click here to view this document in Adobe Acrobat format.
